Association of the Apolipoprotein B/Apolipoprotein A-I Ratio, Metabolic Syndrome Components, Total Cholesterol, and Low-Density Lipoprotein Cholesterol with Insulin Resistance in the Population of Georgia

Table 2

Descriptive characteristics between insulin resistant and insulin sensitive (women).

	Insulin sensitive	Insulin resistant	𝑃 value
Women 𝑛 (%)	491 (75.2)	162 (24.8)
Age	45.5±18.25	50.95±15.07	<.0001
ApoB/ApoA-I ratio	0.62±0.17	1.0±0.23	<.0001
ApoA-I (g/L)	1.08±0.35	1.06±0.47	<.0001
ApoB (g/L)	0.65±0.22	1.01±0.39	<.0001
SP (mmHg)	115±12.4	144±18.38	<.0001
DP (mmHg)	74±8.28	89±11.06	<.0001
WC (cm)	79±10.36	98±7.75	<.0001
BMI (kg/m^2)	23±4.04	34.05±5.48	<.0001
HDL-C (mmol/L)	1.47±0.20	1.20±0.18	<.0001
LDL-C (mmol/L)	2.62±0.38	3.09±0.63	<.0001
FG (mmol/L)	5.0±0.71	6.30±0.53	<.0001
FIns (𝜇U/mL)	8.24±3.31	30.44±9.94	<.0001
Tryg (mmol/L)	1.63±0.15	1.97±0.37	<.0001
TC (mmol/L)	4.20±0.59	5.24±0.55	<.0001
MetS 𝑛 (%)	49 (10)	141 (87)	<.0001
AH 𝑛 (%)	63 (12.8)	122 (75.3)	<.0001
Dyslipidemia 𝑛 (%)	110 (22.4)	155 (95.7)	<.0001

Data are expressed as mean ± SD.
The Mann-Whitney U test was used to compare the data between insulin sensitive and insulin resistant.
Chi-square test was used to compare the prevalence of MetS, AH, and dyslipidemia between insulin sensitive and insulin resistant.
ApoB/ApoA-I ratio: apolipoprotein B/apolipoprotein A-I ratio, ApoA-I: apolipoprotein A-I, ApoB: apolipoprotein B, SP: systolic blood pressure, DP: diastolic blood pressure, WC: waist circumference, BMI: body mass index, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, FG: fasting glucose, FIns: fasting insulin, TG: triglyceride, TC: total cholesterol, HOMA2-IR: homeostasis model assessment of insulin resistance, MetS: metabolic syndrome, and AH: arterial hypertension.
Insulin sensitive (defined as the gender-specific first three quartiles) HOMA2-IR (homeostasis model assessment of insulin resistance) <2.3; insulin resistant (defined as the gender-specific upper quartile) HOMA2-IR (homeostasis model assessment of insulin resistance) ≥2.3.